Table 1.
Baseline characteristics of patients. Information on the total cohort and stratification by the presence of SARS-CoV-2 infection are presented. Data are expressed as number (N) and percentage (%) for categorical variables and as mean ± standard deviation or median [p25–p75] for continuous variables. The p-values of patients who presented SARS-CoV-2 infection vs. those without SARS-CoV-2 infection are detailed.
| Characteristics | Total Cohort | Patients without SARS-CoV-2 Infection | Patients with SARS-CoV-2 Infection | p Value | ||||
|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | |||
| Total | 243 | 100% | 198 | 81.48% | 45 | 18.52% | - | |
| Sex | Female (%) | 120 | 49.38% | 102 | 51.52% | 18 | 40.00% | 0.163 |
| Male (%) | 123 | 50.62% | 96 | 48.48% | 27 | 60.00% | ||
| Age group | 18–39 years (%) | 8 | 3.29% | 8 | 4.04% | 0 | 0.00% | 0.024 |
| 40–49 years (%) | 37 | 15.23% | 35 | 17.68% | 2 | 4.44% | ||
| 50–59 years (%) | 66 | 27.16% | 56 | 28.28% | 10 | 22.22% | ||
| 60–69 years (%) | 95 | 39.09% | 73 | 36.87% | 22 | 48.89% | ||
| 70–79 years (%) | 31 | 12.76% | 23 | 11.62% | 8 | 17.78% | ||
| ≥80 years (%) | 6 | 2.47% | 3 | 1.52% | 3 | 6.67% | ||
| Comorbidities | Diabetes (%) | 110 | 45.27% | 83 | 41.92% | 27 | 60.00% | 0.028 |
| Hypertension (%) | 218 | 89.71% | 177 | 89.39% | 41 | 91.11% | 0.732 | |
| Heart failure (%) | 40 | 16.46% | 31 | 15.66% | 9 | 20.00% | 0.478 | |
| Vascular access | Arteriovenous fistula (%) | 140 | 57.61% | 111 | 56.06% | 29 | 64.44% | 0.304 |
| Hemodialysis catheter (%) | 103 | 42.39% | 87 | 43.94% | 16 | 35.56% | ||
| Hemodialysis parameters | Residual diuresis (%) | 80 | 32.92% | 67 | 33.84% | 13 | 28.89% | 0.524 |
| Hemodialysis vintage (months) | 25 [15–40] | 25 [15–39] | 26 [18–45] | 0.481 | ||||
| Dry weight (kg) | 70.20 ± 7.66 | 70.54 ± 7.45 | 68.71 ± 8.44 | 0.148 | ||||
| Single pool Kt/V (spKt/V) | 1.31 ± 0.20 | 1.31 ± 0.21 | 1.34 ± 0.22 | 0.413 | ||||
| Medications | Angiotensin receptor blockers (%) | 175 | 72.02% | 142 | 71.72% | 33 | 73.33% | 0.827 |
| Calcium channel blockers (%) | 178 | 73.25% | 147 | 74.24% | 31 | 68.89% | 0.464 | |
| Loop diuretics (%) | 46 | 18.93% | 35 | 17.68% | 11 | 24.44% | 0.296 | |
| Vitamin D analogs (%) | 56 | 23.05% | 46 | 23.23% | 10 | 22.22% | 0.885 | |
| Phosphate binders (%) | 209 | 86.01% | 170 | 85.86% | 39 | 86.67% | 0.888 | |
| Calcimimetics (%) | 48 | 19.75% | 40 | 20.20% | 8 | 17.78% | 0.712 | |
| Erythropoietic stimulating agents (%) | 203 | 83.54% | 166 | 83.84% | 37 | 82.22% | 0.792 | |
| Laboratory parameters | Blood ureic nitrogen (mg/dL) | 64.06 ± 12.70 | 64.56 ± 12.31 | 61.86 ± 14.25 | 0.199 | |||
| Intact parathormone (pg/mL) | 565 [284–884] | 572 [275–888] | 511 [293–795] | 0.433 | ||||
| 25-OH vitamin D (ng/mL) | 19.05 ± 8.53 | 19.31 ± 8.57 | 17.93 ± 8.36 | 0.328 | ||||
| Serum phosphate (mg/dL) | 5.15 ± 1.08 | 5.16 ± 1.12 | 5.08 ± 8.78 | 0.664 | ||||
| Total serum calcium (mg/dL) | 8.22 ± 0.98 | 8.21 ± 0.98 | 8.26 ± 1.01 | 0.785 | ||||
| Ferritin (ng/mL) | 467.72 ± 168.45 | 464.82 ± 170.17 | 480.51 ± 161.89 | 0.573 | ||||
| Hemoglobin (g/dL) | 9.45 ± 1.33 | 9.42 ± 1.36 | 9.61 ± 1.20 | 0.379 | ||||
| Intact fibroblast growth factor 23 (pg/mL) | 319 [204–600] | 288 [195–580] | 436 [269–669] | 0.026 | ||||